Publications
620 results found
Reddy D, van Son M, Peters M, et al., 2023, Focal therapy versus radical prostatectomy and external beam radiotherapy as primary treatment options for non-metastatic prostate cancer: results of a cost-effectiveness analysis, JOURNAL OF MEDICAL ECONOMICS, Vol: 26, Pages: 1099-1107, ISSN: 1369-6998
Morote J, Pye H, Campistol M, et al., 2023, Accurate diagnosis of prostate cancer by combining Proclarix with magnetic resonance imaging, BJU INTERNATIONAL, Vol: 132, Pages: 188-195, ISSN: 1464-4096
Light A, Li X, Otieno M, et al., 2023, The 'Leucocyte Coping Capacity' test for identifying radiorecurrent prostate cancer: a pilot study, BJU INTERNATIONAL, ISSN: 1464-4096
Habashy D, Reddy D, Peters M, et al., 2023, Evaluation of Outcomes Following Focal Ablative Therapy for Treatment of Localized Clinically Significant Prostate Cancer in Patients >70 Years: A Multi-institute, Multi-energy 15-Year Experience., J Urol, Vol: 210, Pages: 108-116
PURPOSE: In older patients who do not wish to undergo watchful waiting, focal therapy could be an alternative to the more morbid radical treatment. We evaluated the role of focal therapy in patients 70 years and older as an alternative management modality. MATERIALS AND METHODS: A total of 649 patients across 11 UK sites receiving focal high-intensity focused ultrasound or cryotherapy between June 2006 and July 2020 reported within the UK-based HEAT (HIFU Evaluation and Assessment of Treatment) and ICE (International Cryotherapy Evaluation) registries were evaluated. Primary outcome was failure-free survival, defined by need for more than 1 focal reablation, progression to radical treatment, development of metastases, need for systemic treatment, or prostate cancer-specific death. This was compared to the failure-free survival in patients undergoing radical treatment via a propensity score weighted analysis. RESULTS: Median age was 74 years (IQR: 72, 77) and median follow-up 24 months (IQR: 12, 41). Sixty percent had intermediate-risk disease and 35% high-risk disease. A total of 113 patients (17%) required further treatment. Sixteen had radical treatment and 44 required systemic treatment. Failure-free survival was 82% (95% CI: 76%-87%) at 5 years. Comparing patients who had radical therapy to those who had focal therapy, 5-year failure-free survival was 96% (95% CI: 93%-100%) and 82% (95% CI: 75%-91%) respectively (P < .001). Ninety-three percent of those in the radical treatment arm had received radiotherapy as their primary treatment with its associated use of androgen deprivation therapy, thereby leading to potential overestimation of treatment success in the radical treatment arm, especially given the similar metastases-free and overall survival rates seen. CONCLUSIONS: We propose focal therapy to be an effective management option for the older or comorbid patient who is unsuitable for or not willing to undergo radical treatment.
Mangar S, Abbadasari M, Carollo A, et al., 2023, Understanding Sleep Disturbances in Prostate Cancer-A Scientometric Analysis of Sleep Assessment, Aetiology, and Its Impact on Quality of Life, CANCERS, Vol: 15
Light A, Peters M, Reddy D, et al., 2023, External validation of a risk model predicting failure of salvage focal ablation for prostate cancer, BJU INTERNATIONAL, ISSN: 1464-4096
Raison N, Servian P, Patel A, et al., 2023, Is tumour volume an independent predictor of outcome after radical prostatectomy for high-risk prostate cancer?, PROSTATE CANCER AND PROSTATIC DISEASES, Vol: 26, Pages: 282-286, ISSN: 1365-7852
- Author Web Link
- Cite
- Citations: 2
Eldred-Evans D, Tam H, Sokhi H, et al., 2023, An Evaluation of Screening Pathways Using a Combination of Magnetic Resonance Imaging and Prostate-specific Antigen: Results from the IP1-PROSTAGRAM Study., Eur Urol Oncol, Vol: 6, Pages: 295-302
BACKGROUND: The use of prostate-specific antigen (PSA) testing to screen for prostate cancer has been fraught with under- and overdiagnosis. Short, noncontrast magnetic resonance imaging (MRI) might detect more grade group ≥2 cancers with similar rates of biopsy. OBJECTIVE: To evaluate strategies that combined PSA and MRI to select men based in the community for a prostate biopsy. DESIGN, SETTING, AND PARTICIPANTS: IP1-PROSTAGRAM was a prospective, population-based, paired cohort study of 408 men aged 50-69 yr conducted at seven UK primary care practice and two imaging centres (from October 10, 2018 to May 15, 2019). INTERVENTION: All participants underwent screening with a PSA test, MRI (T2-weighted and diffusion), and transrectal ultrasound (b-mode and elastography). If any test was screen positive, a systematic 12-core biopsy was performed. Additional image-fusion targeted biopsies were taken if the MRI or ultrasound was positive. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We conducted an analysis, set out in the statistical plan a priori, comparing 13 different pathways including PSA-alone, MRI-alone, and a range of PSA thresholds and MRI scores. The performance of each pathway was evaluated focusing on the trade-offs between biopsy referral rates and detection of grade group ≥2 cancers. A targeted biopsy was performed only where the PROSTAGRAM MRI showed a lesion score of 3, 4, or 5. RESULTS AND LIMITATIONS: The standard PSA pathway (PSA ≥3 ng/ml + systematic biopsy) would lead to 10% of men being referred for a biopsy and a 1.0% detection rate of grade group ≥2 cancers. Pathways that relied on MRI alone set at a threshold score of 3 for a biopsy led to higher biopsy rates, but with benefit of high cancer detection rates. The pathway that combined an initial low PSA threshold (≥1.0 ng/ml) and MRI score ≥4 accurately identified a high rate of grade group ≥2 cancers (2.5%, 95% confidence interval 1.3-4.6) while recommending fewe
Brunckhorst O, Liszka J, James C, et al., 2023, Mental wellbeing and quality of life in prostate cancer (MIND-P): Protocol for a multi-institutional prospective cohort study, PLOS ONE, Vol: 18, ISSN: 1932-6203
Connor MJJ, Gorin MAA, Eldred-Evans D, et al., 2023, Landmarks in the evolution of prostate biopsy, NATURE REVIEWS UROLOGY, Vol: 20, Pages: 241-258, ISSN: 1759-4812
- Author Web Link
- Cite
- Citations: 5
Shah TT, Kanthabalan A, Otieno M, et al., 2023, Magnetic Resonance Imaging and targeted biopsies compared to transperineal mapping biopsies prior to salvage focal therapy/ablation in localised and metastatic recurrent prostate cancer after radiotherapy. Primary Outcomes from the FORECAST Trial (vol 81, pg 598, 2022), EUROPEAN UROLOGY, Vol: 83, Pages: e117-e118, ISSN: 0302-2838
Stavrinides V, Norris JM, Karapanagiotis S, et al., 2023, Regional Histopathology and Prostate MRI Positivity: A Secondary Analysis of the PROMIS Trial, RADIOLOGY, Vol: 307, ISSN: 0033-8419
- Author Web Link
- Cite
- Citations: 1
Eldred-Evans D, Connor MJ, Tanaka MB, et al., 2023, The rapid assessment for prostate imaging and diagnosis (RAPID) prostate cancer diagnostic pathway, BJU INTERNATIONAL, Vol: 131, Pages: 461-470, ISSN: 1464-4096
- Author Web Link
- Cite
- Citations: 3
Light A, Lazic S, Bayne M, et al., 2023, THE DIAGNOSTIC ACCURACY OF <SUP>68</SUP>GA-PSMA PET/CT VERSUS MULTIPARAMETRIC MRI FOR LOCALIZING INTRA-PROSTATIC RADIORECURRENT PROSTATE CANCER, Publisher: LIPPINCOTT WILLIAMS & WILKINS, Pages: E766-E766, ISSN: 0022-5347
Light A, Peters M, Kanthabalan A, et al., 2023, EXTERNAL VALIDATION OF A RISK SCORE PREDICTING FAILURE AFTER SALVAGE FOCAL THERAPY FOR LOCALIZED RADIORECURRENT PROSTATE CANCER: AN ANALYSIS FROM THE FOCAL RECURRENT ASSESSMENT AND SALVAGE TREATMENT (FORECAST) TRIAL, Publisher: LIPPINCOTT WILLIAMS & WILKINS, Pages: E1035-E1036, ISSN: 0022-5347
Light A, Kanthabalan A, Pavlou M, et al., 2023, SYSTEMATIC AND MRI-TARGETED BIOPSY STRATEGIES FOR THE DETECTION OF RADIORECURRENT PROSTATE CANCER: AN ANALYSIS FROM THE FOCAL RECURRENT ASSESSMENT AND SALVAGE TREATMENT (FORECAST) TRIAL, Publisher: LIPPINCOTT WILLIAMS & WILKINS, Pages: E610-E611, ISSN: 0022-5347
Light A, Kanthabalan A, Pavlou M, et al., 2023, TUMOR CHARACTERISTICS OF MULTIPARAMETRIC MRI-DETECTED AND -UNDETECTED LESIONS IN PATIENTS WITH SUSPECTED RADIORECURRENT PROSTATE CANCER: AN ANALYSIS FROM THE FOCAL RECURRENT ASSESSMENT AND SALVAGE TREATMENT (FORECAST) TRIAL, American Urological Association Meeting (AUA), Publisher: LIPPINCOTT WILLIAMS & WILKINS, Pages: E612-E613, ISSN: 0022-5347
Jaipuria J, Pchejetski D, Eldred-Evans D, et al., 2023, CIRCULATING CHROMOSOME CONFORMATION SIGNATURES ENHANCE THE ACCURACY OF PSA FOR DETECTING PROSTATE CANCER- RESULTSFROMPERFORMANCE OF THE EPISWITCH™ PCA TEST IN THE PROSTAGRAM TRIAL, Publisher: LIPPINCOTT WILLIAMS & WILKINS, Pages: E545-E546, ISSN: 0022-5347
Eldred-Evans D, Winkler M, Klimowska-Nassar N, et al., 2023, Perceived patient burden and acceptability of MRI in comparison to PSA and ultrasound: results from the IP1-PROSTAGRAM study, PROSTATE CANCER AND PROSTATIC DISEASES, ISSN: 1365-7852
Ahmed HU, Frangou E, Marsden T, et al., 2023, ReIMAGINE Prostate Cancer Risk: A prospective cohort study in men with a suspicion of prostate cancer who are referred onto an MRI-based diagnostic pathway with donation of tissue, blood, urine and imaging for biomarker analyses, Publisher: ELSEVIER, Pages: S102-S103, ISSN: 0302-2838
Bass EJ, Connor MJ, Adzawoloo-Andersson I, et al., 2023, Can we predict when non-targeted systematic prostate biopsies need to be performed? Outcomes from the multicentre RAPIDOnline 3,853 patient cohort, Publisher: ELSEVIER, Pages: S248-S248, ISSN: 0302-2838
Uthman AKAA, Connor MJ, Khoo C, et al., 2023, Predictors of Trial-Without-Catheter (TWOC) outcome in 384 patients treated with Rezum thermotherapy?, Publisher: ELSEVIER, Pages: S324-S324, ISSN: 0302-2838
Uthman AKAA, Connor MJ, Khoo C, et al., 2023, Rezum thermotherapy for large prostate volumes (>/=80 cc): 2-year clinical outcomes, Publisher: ELSEVIER, Pages: S327-S327, ISSN: 0302-2838
Light A, Mayor N, Shah TT, et al., 2023, MRI interpretation and assessment criteria for imaging after focal therapy for prostate cancer: A systematic review, Publisher: ELSEVIER, Pages: S152-S153, ISSN: 0302-2838
Bass EJ, Fiorentino F, Szigeti M, et al., 2023, Novel trial designs in localised prostate cancer: Pilot phase results from the prostate pathway embedded comparative trial (ip3-prospect), Publisher: ELSEVIER, Pages: S742-S743, ISSN: 0302-2838
Rowley M, Olalla SA, Brown LC, et al., 2023, The need for advanced analytical methods for big data in urology: A first application from the ReIMAGINE risk study, Publisher: ELSEVIER, Pages: S440-S441, ISSN: 0302-2838
Rakauskas A, Peters M, Ball D, et al., 2023, Clinical-Prostate cancer The impact of local staging of prostate cancer determined on MRI or DRE at time of radical prostatectomy on progression-free survival: A Will Rogers phenomenon, UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, Vol: 41, ISSN: 1078-1439
- Author Web Link
- Cite
- Citations: 1
Merriel SWD, Seggie A, Ahmed H, 2023, Diagnosis of prostate cancer in primary care: navigating updated clinical guidance, BRITISH JOURNAL OF GENERAL PRACTICE, Vol: 73, Pages: 54-55, ISSN: 0960-1643
- Author Web Link
- Cite
- Citations: 1
Pchejetski D, Hunter E, Dezfouli M, et al., 2023, Circulating Chromosome Conformation Signatures Significantly Enhance PSA Positive Predicting Value and Overall Accuracy for Prostate Cancer Detection, CANCERS, Vol: 15
- Author Web Link
- Cite
- Citations: 2
Bass EJJ, Ahmed HUU, 2023, Age-related PSA testing for prostate cancer: NICE recommendation 1.6.3, BJU INTERNATIONAL, Vol: 131, Pages: 130-131, ISSN: 1464-4096
- Author Web Link
- Cite
- Citations: 1
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.